Schizophrenia - new treatments soon.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39511776.
- Also identified by DOI 10.1192/bjp.2024.195.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antipsychotic medications targeting dopamine receptors were identified 70 years ago. Recent clinical trials have shown that agonists of muscarinic acetylcholinergic receptors can improve both psychotic and negative symptoms in schizophrenia. Here, this new approach to the treatment of schizophrenia is reviewed in anticipation of the drugs being licensed clinically.
Medical subject headings
- Schizophrenia
- Antipsychotic Agents
- Muscarinic Agonists